The eligible study included for IgM ELISA accuracy analysis [41] was conducted in France, French Polynesia, Guadeloupe, Guyana, and Martinique, and was a two-gate design study that included patients with suspected leptospirosis and controls from patients with evidence of recent infection for dengue and syphilis, or from healthy blood donors. The gene discussed is CD40LG; the disease is leptospirosis.